Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab
L23-385-01
Phase 2 small_molecule active
Quick answer
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Lung Cancer (NSCLC) is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Lung Cancer (NSCLC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active